Match!
Justine V. Cohen
Harvard University
67Publications
13H-index
1,067Citations
Publications 73
Newest
PURPOSEThe risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI advers...
Source
#1Yousef R. Badran (Harvard University)H-Index: 5
#2Justine V. Cohen (Harvard University)H-Index: 13
Last.Michael Dougan (Harvard University)H-Index: 17
view all 6 authors...
Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irEC) is among the most common severe irAEs leading to the discontinuation of ICIs. Inhibitors of tumor necrosis factor alpha (anti-TNFα) have been used to treat irEC. Recent animal studies have shown that concurrent treatment with anti-TNFα and ICIs improves tumor respons...
Source
#1Elisa Bello (Harvard University)H-Index: 1
#2Justine V. Cohen (Harvard University)H-Index: 13
Last.Michael Dougan (Harvard University)H-Index: 17
view all 4 authors...
Background Alongside its clinical success, checkpoint blockade has also given rise to a set of immune-related adverse events (irAEs). In addition to causing considerable morbidity and even mortality, irAEs may limit the success and scope of immunotherapy. Most irAEs arise at mucosal barriers, including the gastrointestinal mucosa, leading most commonly to colitis, though both gastritis and enteritis can result from checkpoint blockade. While guidelines generally recommend confirmatory testing fo...
2 CitationsSource
#1Magid Awadalla (Harvard University)H-Index: 4
#2Doll Lauren Alexandra Golden (Harvard University)H-Index: 1
Last.Tomas G. Neilan (Harvard University)H-Index: 32
view all 37 authors...
Background Influenza vaccination (FV) is recommended for patients with cancer. Recent data suggested that the administration of the FV was associated with an increase in immune-related adverse events (irAEs) among patients on immune checkpoint inhibitors (ICIs). Myocarditis is an uncommon but serious complication of ICIs and may also result from infection with influenza. There are no data testing the relationship between FV and the development of myocarditis on ICIs.
4 CitationsSource
Source
Source
Source
Source
Source
Source
12345678